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Chronic hepatitis C (CHC) is a major cause of  liver cirrhosis and hepatocellular 
carcinoma.  Steat osi s occurs i n alm ost  50% of pat ient s wi t h CHC,  who m ake a fast er 
progression to cirrhosis. The "atypical " patients are registred too, with normal values of 
blood sugar, cholesterol, triglycerides, BMI, body weight having non-alcoholic 
steatohepatitis (NASH) and CHC. The hsCRP levels rise before and simultaneously with 
the chronic hepatitis and cirrhosis progression, therefore, it is a useful prognostic 
parameter. According to our knowledge, there are no sufficient data concerning hsCRP 
concentrations in CHC patients, although it predicts or detects different grades of 
cirrhosis. For that reason, the aim of our research was to assess  the hsCRP in patients 
with CHC. 
  The investigation involved 45 patients (28 males and 17 females), mean age 41±15 
years, with CHC, without any accompanying disease. The control group consisted of 45 
healthy volunteers (22 males, 23 females), mean age 34±10 years. The CHC patients' 
group was divided into two subgroups, the first, which consisted of 23 patients with 
evidenced histological signs of mild steatosis, and the second one, comprising 22 
patients without the mentioned signs; hsCRP concentrations were measured in each 
patients' (sub)group. 
  The findings indicate that the hsCRP value had a statistically significant increase in 
the CHC patients' group compared to the control group (p<0.05). In the CHC and mild 
liver steatosis patients subgroup, even more statistically significant hsCRP increase 
occured compared to the other subgroup (p<0.001). 
  It can be concluded, based on the acquired results, that hsCRP should be considered 
as a CHC progression prognostic factor, in o r d e r  t o  m a k e  a  w e l l - t i m e d  a n d  s p e c i a l  
therapeutic approach to the CHC individuals even more prone to the disease 
progression. Acta Medica Medianae 2010;49(3):14-18. 
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Introduction 
 
Hepatitis C virus (HCV) is a leader in 
inducing chronic liver disease worldwide. Chronic 
hepatitis C (CHC) is a major cause of liver 
cirrhosis and hepatocellular carcinoma. The HCV 
infection characterizes by its predisposition to 
chronicity. Because of its high genetic variability, 
HCV has the ability of escaping the host’s 
immune response. This virus is not directly 
cytopathic and the liver damage is mostly a 
consequence of immune-mediated mechanisms, 
predominantly of the T helper cells. Co-factors 
influencing the disease outcome include age, 
gender, alcohol consumption. Recent studies 
have shown that the combined peginterpheron 
and ribavirin therapy leads to a sustained 
virologic response in half of the CHC patients, on 
an average (1,2). 
C-reactive protein (CRP) is a non-specific 
marker of inflammation and a predictor of a 
coronary heart disease, cardiovascular disorders, 
subclinical vascular diseases. Available cognizances 
presume that moderately increased CRP directs 
attention to elevated risk of myocardial infarction. 
The CRP concentration is affected by: body mass 
index (BMI), diabetes, hypertension, cigarette 
smoking, estrogen replacement therapy, as well 
as the presence of rheumatoid arthritis, chronic 
lung diseases, acute viral infections. High 
sensitivity CRP (hsCRP) has been even more 
often proposed for heart diseases risk evaluation, 
for the purpose of preventive procedures (3). Acta Medica Medianae 2010,Vol.49(3)   High sensitivity C-reactive protein as prediction factor... 
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Although not being a specific biomarker, its 
concentrations rise fast as a response to tissue 
damage, infections and other inflammatory 
phenomena, such as autoimmune diseases and 
malignances (4). 
Higher sensitivity of hsCRP unlike the 
"usual" CRP is reflected through lower minimal 
normal value as well as lower range of reference 
values (from 0 to 1 mg/l, matched with the 
"usual" hsCRP, with 0 to 5 mg/l), so its predictive 
ability is much more accurate concerning future 
cardiovascular pathologic events in basically 
healthy individuals (5). Its use is particularly 
frequent in the pediatric population (6-8).  
Levels of CRP raise parallelly with the 
chronic liver disease progression, such as chronic 
hepatitis and liver cirrhosis, as well as before the 
progression beginning, therefore it is a useful 
prognostic parameter (9). It is interesting that 
hsCRP concentrations decrease linearly with the 
serum bilirubin increase. Also, there was noticed 
a coherence of increased hsCRP concentrations 
with the non-alcoholic steatohepatitis (NASH), 
frequent CHC accompanist (10). Patients with the 
active form of the NASH (grade 2-3) have even 
more increased hsCRP concentrations compared 
to those with the stagnant form (grade 1 or the 
simple steatosis), so hsCRP could be a promising 
biomarker for screening the NASH (11). 
According to our knowledge, there are not 
sufficient data concerning hsCRP concentration in 
CHC patients, although it predicts emergence or 
the existence of NASH. From that reason, 
measuring hsCRP concentration in CHC patients 
is the aim of our study. 
 
Patients and methodology 
 
The study was carried out on 45 patients 
(28 males and 17 females), mean age 41±15 
years, with chronic HCV infection, selected 
among the patients anamnestically and clinically 
examined in the Infectious Disease Clinic of 
Clinical Centre Niš. Diagnosis of the CHC was 
established on the basis of elevated amino-
transferases serum activity, positive anti-HCV 
antibodies (the third generation ELISA, Bioelisa 
ELx800 Biokit, Spain) and presence of serum 
HCV-RNA (PCR testing), and histological proof of 
chronic hepatitis. Patients with the additional 
diseases (acute, chronic or autoimmune, neither 
of the liver nor of the other organ systems) were 
excluded of the reserch (the attention was 
particularly addressed to potential hsCRP increase 
including disorders), after the detailed clinical 
and laboratory examinations, apart from the CHC 
patients subgroup with the mild steatosis, patho-
histologically evaluated. Only the patients with no 
pathohistologically diagnosed signs of liver 
fibrosis nor cirrhosis were enrolled into the study. 
The control group consisted of 45 healthy 
volunteers (22 males, 23 females), mean age 
34±10 years, selected after the general systematic 
examination, who were seronegative of HCV, 
HBV, HIV, HbsAg, total anti-HBc antibodies and 
anti-HCV testing, without the previous history of 
hepatitis or the chronic alcoholism, with no 
laboratory results abnormalities including liver 
function testing. All the patients and the control 
group individuals signed the inform consent. The 
aspartat aminotransferase (AST) and the alanin 
aminotransferase activity were determined by a 
ready-made test of Ellitech Company, on the 
biochemical analyzer BTS-370 (BioSystems). The 
values of enzyme activity were expressed in U/l. 
The measurment of hsCRP was performed by a 
commercial test of the Dade Behring company, 
on the analyzer Dimension Expand. The values 
were expressed in mg/l. In further investigation, 
the CHC patients' group was divided into the two 
subgroups, the first, which consisted of 23 
patients with the presence of mild steatosis 
histological signs, ant the second, which included 
22 patients without the above mentioned signs; 
so hsCRP concentrations were determined on 
both subgroups. 
The statistical analysis was performed by 
SPSS (Statistical Package for the Social Sciences 
Program) for Windows, version 11,0, whereby 
the results were presented in tables. The 
Students' t-test was applied on account of 
comparing the mean values of the laboratory 
parameters of the CHC patients and the control 
group, as well as the two CHC patients subgroup. 
A value of p<0.05 was considered statistically 
significant. 
  
Results 
 
  The obtained results demonstrated that 
hsCRP values were significantly increased in the 
CHC patients’ group compared to the control 
group (p<0.05) (Table 1). As it was expected, 
the enzymes AST and ALT activity values had a 
statistically significant increase in the CHC 
patients compared to the controls. The CHC and 
liver steatosis including subgroup had an even 
more statistically significant hsCRP rise compared 
to no histologically proven liver steatosis subgroup  
(p<0.001) (Table 2). 
 
Table 1. Concentrations of  hsCRP and plasma AST and 
ALT activity in the CHC patients and  control group 
 
  CHC patients 
(N=45) 
Control 
group 
(N=45) 
hsCRP (mg/l)  3.44±0.52 *  0.11±0.09 
AST  (U/l)  79.43±16.32 ***  20.34±6.03 
ALT  (U/l)  96.97±23.57 ***  19.49±5.92 
  Data are shown as mean±SD. *p<0.05; ***p<0.001 
 
Table 2. Concentrations of  hsCRP in plasma of  CHC 
patients  with and without  presence of  mild liver 
steatosis 
 
 
CHC patients with 
mild steatosis 
(N=23) 
CHC patients 
without mild 
steatosis 
 (N=22) 
hsCRP (mg/l)  6.26±1.09 ***  0.57±0.13 
 Data are shown as mean±SD. ***p<0. 001 High sensitivity C-reactive protein as prediction factor...                                   Lidija Popović-Dragonjić et al. 
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Discussion 
 
Not enough of adequate data concerning 
hsCRP in CHC patients could be found in 
literature recently. Our research confirmed the 
presumption that hsCRP, as an inflammatory 
marker, is also increased in CHC, being an 
inflammatory liver disease. The result of 
increased hsCRP concentration in pathohisto-
logically proven mild steatosis without any 
accompanying clinical and laboratory indicators of 
itself,  was expected, too. The mentioned results 
pointed out the eventual significance of 
measuring hsCRP in CHC patients, in the sense of 
being a prediction factor, and well-timed detecting 
of "atypical" patients with potentially increased 
risk of disease progression.  
Although a mild steatosis per se is usually 
benign, patients with histologically proven NASH 
can make a progression towards liver cirrhosis. 
Steatosis occurs in almost 50% of HCV infected 
patients. Liver steatosis in HCV infection facilitates 
the mentioned disease progression. A significant 
fibrosis was noticed in HCV infected patients, who 
were confirmed a liver steatosis or NASH by liver 
biopsy (12). The presence of liver steatosis 
correlates with the fibrosis grade in CHC patients, 
which emphasizes the importance of the pheno-
mena (13). 
After the complex multivariate analyses, 
there was noticed an occurrence of normal blood 
levels of glucose, triglycerides, and other indicators 
of NASH, in patients with NASH and CHC (14). 
Also, even the patients without signs of insulin 
resistance, with low cholesterol and triglycerides 
levels, and having BMI and body weight in 
frames of normal values, could develop NASH 
(15, 16). 
From the above mentioned studies, one 
could have concluded that even the "atypical" 
patients (with unnoticeable clinical and laboratory 
finding) may develop liver steatosis, which leads 
CHC patients to the further disease progression. 
Therefore, a diagnostic parameter for anticipating 
liver steatosis emergence is needed, in order to 
have a well-timed and timely initiated therapy, 
especially for not considering liver biopsy anymore 
as inevitable diagnostic procedure (17). 
Hepatitis C is still a serious progressive 
chronic liver disease, despite advancements in 
therapy methods. Viral afctors and host chara-
cteristics are related to progression towards 
fibrosis,cirrhosis and therapy response. Steatosis 
is for a long time regarded as a frequent 
histological finding in hepatitis C. Recent evidence 
propose steatosis in hepatitis C as a non-
accidental finding, which could be a consequence 
of various cytopathic effects, synergistic mechanisms 
of viral proteins with the host metabolism of the 
lipids and factors related to steatosis or steato-
hepatitis in NASH: visceral obesity, diabetes type 
2, insulin resistence. Steatosis increases the 
incidence of fibrosis towards cirrhosis progression 
(18). 
In CHC, the prevalence of steatosis is two 
and a half times increased than expected, 
compared to non-infected individuals, which 
confirms that HCV participates in its development. In 
some studies it has been reported (although 
there are some who stand against) that NASH 
occurs more often in HCV patients with genotype 
1 and increased BMI, but also with genotype 3 
and increased viral load. Anyway, patients with 
increased progression grade of NASH have less 
chances to have a positive interferon therapy 
response (19). In patients with CHC, NASH and 
normal BMI, there is a frequent confusion in the 
interpretation of the examination results and the 
proper diagnosis establishing; in the meanwhile, 
patient’s health condition is getting worse (20). 
C-reactive protein plays an important role 
in inflammatory processes connected with metabolic 
syndrome, which is more often associated with 
individuals with CHC than HCV negative population 
(21). 
High sensitivity CRP could be used in the 
beginning as a detector of the liver inflammatory 
response in patients with the metabolic syndrome. 
Limitation of the sensitivity and the specificity of 
such testing could be annulled by identifying, i.e. 
defining various grades of hepatic inflammation 
(22). 
In our case, circumstances of CHC presence 
in patients without other accompanying disorders 
are facilitating easier reclining on hsCRP concen-
trations measuring. Some researches give information 
of significant steatosis diminishing in patients 
with the sustained virologic response to the 
therapy. On the other hand, the recurrence of 
steatosis in some patients is registered after the 
HCV infection relapse. The presence of fatty 
infiltrations in CHC patients is a usual finding 
during the ultra-sound examination, although the 
definite diagnosis is ungrateful, because the 
displayed signs of the "bright liver" are often 
present in hepatic fibrosis and inflammation. On 
the other hand, laboratory analysis in patients 
with a chronic course did not always correlate 
with the evolution of the disease, when the 
clinical course is mostly mild (23). Pathohisto-
logical finding is the most accurate, but the liver 
biopsy is not infallibly indicated in all the 
patients, neither all of them give their consents 
for the procedure (24-27). 
 
Conclusion 
 
High sensitivity CRP should be considered 
as a CHC progression factor of prediction, having 
in mind statistically significant increase of its 
concentrations in CHC patients compared to the 
healthy population, and in patients with the liver 
steatosis in comparison with the ones without the 
steatosis, within the CHC population. 
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VISOKO SENZITIVNI C-REAKTIVNI PROTEIN KAO PREDIKTORNI 
FAKTOR PROGRESIJE BOLESTI KOD BOLESNIKA SA HRONIČNIM 
HEPATITISOM C I BLAGOM STEATOZOM JETRE 
 
Lidija Popović-Dragonjić, Maja Jovanović, Miodrag Vrbić, Ljiljana Konstantinović, Velimir Kostić i Ivan 
Dragonjić
 
 
 
Hronični hepatitis C (HHC) je glavni uzrok ciroze jetre i hepatocelularnog karcinoma. 
Steatoza je prisutna kod skoro 50% bolesnika sa HHC i oni brže progrediraju ka cirozi. 
Registrovani su i "atipični" bolesnici, normalnih vrednosti glukoze, holesterola i 
triglicerida u krvi, BMI, telesne mase sa nealkoholnim steatohepatitisom (NASH) i HHC. 
Nivoi hsCRP rastu pre i paralelno sa progresijom hroničnog hepatitisa i ciroze jetre, te je 
koristan prognostički parameter. Prema našim saznanjima, nema dovoljno podataka o 
koncentraciji hsCRP kod belesnika sa HHC, iako predviđa ili detektuje različite stepene 
steatoze. Iz tog razloga je određivanje koncentracije hsCRP kod bolesnika sa HHC cilj 
našeg rada. 
U istraživanje je uključeno 45 bolesnika (28 muškaraca i 17 žena), prosečne starosti 
41±15 godina, sa HHC, bez pridruženih oboljenja. Kontrolnu grupu činilo je 45 zdravih 
dobrovoljaca (22 muškarca i 23 žene), prosečne starosti 34±10 godina. Grupa bolesnika 
sa HHC podeljena je u dve podgrupe, prvu, koja se sastojala od 23 bolesnika sa 
prisutnim histološkim znacima blage steatoze, i drugu, koju su činila 22 bolesnika bez 
pomenutih znakova; te je kod svih (pod)grupa merena koncentracija hsCRP.  
Dobijeni rezultati pokazuju da je vrednost hsCRP statistički značajno povišena u 
grupi bolesnika sa CHC u poređenju sa kontrolnom grupom (p<0.05). Kod podgrupe sa 
HHC i blagom steatozom jetre došlo je do statistički značajnijeg porasta hsCRP u odnosu 
na drugu podgrupu (p<0.001).   
Iz priloženih rezultata može se zaključiti da bi hsCRP trebalo uzeti u obzir kao 
prognostički faktor progresije HHC, radi posebnog i blagovremenog terapijskog pristupa 
osobama sa HHC sklonijim progresiji bolesti. Acta Medica Medianae 2010;49(3):14-18. 
 
Ključne reči: hronični hepatitis C, visoko senzitivni C-reaktivni protein, steatoza jetre 
 